The long-term outcome of patients with polycystic liver disease treated with lanreotide

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 2, 2012, Pages 266-274

  Chrispijn, M ^a   Nevens, F ^b   Gevers, T J G ^a   Vanslembrouck, R ^b   Van Oijen, M G H ^a,c   Coudyzer, W ^b   Hoffmann, A L ^a   Dekker, H M ^a   De Man, R A ^d   Van Keimpema, L ^a   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOPEPTIN; PLACEBO;

ABDOMINAL CRAMP; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; KIDNEY SIZE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LONG TERM CARE; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; STEATORRHEA; TREATMENT DURATION; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; CYSTS; FEMALE; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 83855161557     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04923.x     Document Type: Article

References (22)

1. Drenth JP, Chrispijn M, Bergmann C,. Congenital fibrocystic liver diseases. Best Pract Res Clin Gastroenterol 2010; 24: 573-84.
2. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE,. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-30.
3. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort Clin J Am Soc Nephrol 2006; 1: 64-9.
4. van Keimpema L, de Koning DB, van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011; 31: 92-8.
5. Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr, Nogorney DM,. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1186-92. (Pubitemid 24977100)
6. Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM,. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009; 250: 112-8.
7. Pirenne J, Aerts R, Yoong K, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001; 7: 238-45. (Pubitemid 32243820)
8. Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34: 702-13.
9. Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol Cell Physiol 2003; 284: C1205-14. (Pubitemid 36457401)
10. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173: 1637-46.
11. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, Larusso NF,. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49: 160-74.
12. Alvaro D, Gigliozzi A, Attili AF,. Regulation and deregulation of cholangiocyte proliferation. J Hepatol 2000; 33: 333-40. (Pubitemid 30485240)
13. van Keimpema L, de Man RA, Drenth JP,. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008; 57: 1338-9.
14. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-61.
15. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-9.
16. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.
17. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB,. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 2006; 51: 1509-15. (Pubitemid 44379291)
18. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36) I Conceptual framework and item selection. Med Care 1992; 30: 473-83.
19. van Keimpema L, Drenth JP,. Effect of octreotide on polycystic liver volume. Liver Int 2010; 30: 633-4.
20. Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME,. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34: 235-42
21. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA,. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 2005; 4: 43-53. (Pubitemid 40129110)
22. Modlin IM, Pavel M, Kidd M, Gustafsson BI,. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.